These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30626779)

  • 1. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.
    Wang D; You D; Li L
    J Toxicol Sci; 2019; 44(1):47-56. PubMed ID: 30626779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
    Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
    Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
    Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
    Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma.
    Zhang PF; Wu J; Luo JH; Li KS; Wang F; Huang W; Wu Y; Gao SP; Zhang XM; Zhang PN
    Aging (Albany NY); 2019 Oct; 11(19):8204-8216. PubMed ID: 31581131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
    Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
    Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
    Li J; Jiang K; Qiu X; Li M; Hao Q; Wei L; Zhang W; Chen B; Xin X
    BMB Rep; 2014 Jan; 47(1):33-8. PubMed ID: 24209634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular vesicles carrying miR-6836 derived from resistant tumor cells transfer cisplatin resistance of epithelial ovarian cancer via DLG2-YAP1 signaling pathway.
    Zou Y; Zhao Z; Wang J; Ma L; Liu Y; Sun L; Song Y
    Int J Biol Sci; 2023; 19(10):3099-3114. PubMed ID: 37416779
    [No Abstract]   [Full Text] [Related]  

  • 11. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
    Nie S; Zhang L; Liu J; Wan Y; Jiang Y; Yang J; Sun R; Ma X; Sun G; Meng H; Xu M; Cheng W
    J Exp Clin Cancer Res; 2021 Sep; 40(1):284. PubMed ID: 34496932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
    Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
    Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
    Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
    Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis.
    Li C; Wang Q; Luo Y; Xiang J
    Anal Cell Pathol (Amst); 2022; 2022():5632164. PubMed ID: 36247876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
    Cao L; Wan Q; Li F; Tang CE
    BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The downregulation of miR-509-3p expression by collagen type XI alpha 1-regulated hypermethylation facilitates cancer progression and chemoresistance via the DNA methyltransferase 1/Small ubiquitin-like modifier-3 axis in ovarian cancer cells.
    Wu YH; Huang YF; Wu PY; Chang TH; Huang SC; Chou CY
    J Ovarian Res; 2023 Jun; 16(1):124. PubMed ID: 37386587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer.
    Wallace-Povirk A; O'Connor C; Dekhne AS; Bao X; Nayeen MJ; Schneider M; Katinas JM; Wong-Roushar J; Kim S; Polin L; Li J; Back JB; Dann CE; Gangjee A; Hou Z; Matherly LH
    Mol Cancer Ther; 2024 Jun; 23(6):809-822. PubMed ID: 38377173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway.
    Pei L; Zhao F; Zhang Y
    Apoptosis; 2024 Feb; 29(1-2):210-228. PubMed ID: 38087046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.